Propeller Health and Novartis collaborate to develop intelligent slow-resistance lung sensors
Propeller Health, a provider of respiratory health management solutions, has a mobile platform that includes sensors, mobile applications, analytics and services to support respiratory health management.
Propeller's smart sensors continuously track patients' medications and record when and where they use the inhaler. The sensor is a small device that can be attached to the top of an existing inhaler. Through objective data collection and feedback in the software, patients can better understand and manage asthma or chronic obstructive pulmonary disease.
Recently, Propeller and Novartis Pharmaceuticals have established a partnership to develop a smart sensor customized for the Breezhaer series of chronic obstructive pulmonary disease (Ultibro Breezhaler, Onbrez Breezhaler and Seebri Breezhaler) to integrate these drugs into Propeller's digital healthcare in Europe. platform.
This marks Novartis as the fifth pharmaceutical company to establish a partnership with Propeller, and Propeller has partnered with Boehringer Ingelheim and GlaxoSmithKline. Propeller has partnered with the top three chronic obstructive lung pharmaceutical companies to strengthen the company's most important platform for respiratory digital health.
"Chronic obstructive pulmonary disease" (COPD) is highly disabling (breathing difficulties lead to loss of exercise in daily life), the main symptoms are cough, cough and difficulty breathing. Chronic obstructive pulmonary disease currently ranks 4th in the world for dead diseases, and its medicines are expensive. By 2020, it will rank fifth in the world's disease burden. In China, the prevalence rate of people over 40 years old is about 8.2%, and the prevalence rate of men is as high as 12.4%. According to this estimation, the number of patients with COPD in China is close to 50 million. .
Drug therapy in patients with chronic obstructive pulmonary disease is critical and has become an important issue in the study of respiratory diseases. However, chronic obstructive pulmonary drugs are expensive, and many patients only see the doctor when the disease is aggravated. Once the condition is relieved, they are quickly stopped. Repeatedly, the lung function progresses progressively, and treatment becomes more and more difficult, forming a vicious circle. The only way to break this vicious circle is to use the main focus of prevention and control of COPD in the stable period, and most of the disease can be prevented by appropriate management. At present, 60% of asthma patients are still not well controlled. Therefore, the data on the amount of drug use and frequency of use in patients with chronic obstructive pulmonary disease is very important for doctors.
The patient uses the Breezhaler smart inhaler, which records the patient's inhalation time, number of times, and inhalation, and transmits the data to the mobile phone app via Bluetooth. As a result, Propeller's intelligent big data platform can take intelligent interventions to remind patients to establish drug compliance.
“We are pleased to work with Novartis to connect Breezhaler equipment to the Propeller platform. This is a professional respiratory medicine series that represents the next step in bringing a valuable approach to patient respiratory therapy.†Propeller CEO David Van Scikle said, "With these drug sensors and data, Propeller will strengthen the relationship between patients and doctors to help them build effective treatments together."
Van Scikle believes that the digitalization of respiratory medicine is fast because the compliance rate of patients with respiratory diseases is very low. Propeller's goal is to use Propeller's smart products for all inhaled drugs to build a broad respiratory digital medical platform.
Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.
Calquence,Acalabrutinib Cll,Calquence Cll,Acalabrutinib Ema
Shijiazhuang Dingmin pharmaceutical Sciences Co.,Ltd , https://www.dingminpharma.com